Skip to main content
Vita 34 AG logo

Vita 34 AG — Investor Relations & Filings

Ticker · V3V ISIN · DE000A0BL849 LEI · 529900OEWA4GSZEZ4P40 F Human health and social work activities
Open in API
Filings indexed 794 across all filing types
Latest filing 2014-06-23 Declaration of Voting R…
Country DE Germany
Listing F V3V

About Vita 34 AG

https://www.vita34.de/en/

Vita 34 AG is a biobank specializing in the cryopreservation of stem cells derived from umbilical cord blood and tissue. Established in 1997 as the first private cord blood bank in Europe, the company offers services for the long-term storage of perinatal stem cells for potential future medical applications. The service portfolio includes providing collection kits for childbirth, handling logistics, processing the biological material, and storing the stem cell deposits under cryogenic conditions. These services are offered to expectant parents as a form of private medical provision for their child and family. As part of the Famicord Group, Vita 34 is also involved in research and development related to cell-based therapies.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text explicitly states it is a 'Voting Rights Announcement' disseminated via DGAP. It details that HSCI OJSC informed Vita 34 AG that its voting rights fell below a specific threshold (15%) on June 19, 2014, corresponding to 452,773 Voting Rights. This directly matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (Code: DVA). Although it is a regulatory announcement, DVA is a more specific category than the general RNS.
2014-06-23 English
Vita 34 AG Expands its R&D Activities to Include Research Projects Involving Autologous Fatty Tissue and a New Project Phase in the Production of Active Agents
Regulatory Filings Classification · 99% confidence The document is a news release dated June 18, 2014, detailing Vita 34 AG's expansion of R&D activities, including new research projects on autologous fatty tissue and active agent production. It discusses strategic plans, funding, and company profile information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). It is an announcement of corporate activity and strategy, which fits best under the general category for corporate news announcements that don't fit other specific categories, or potentially an Investor Presentation (IP) if it were a slide deck, but given the format and content (a press release style announcement), it aligns most closely with a general regulatory announcement or news release. Since it is a detailed announcement of corporate strategy and R&D progress, and not just a notice of a report being published, it is classified as a Regulatory Filing (RNS) as a broad category for corporate news releases not covered by more specific codes like ER or IR.
2014-06-18 English
DGAP-DD: Vita 34 AG english
Director's Dealing Classification · 100% confidence The document explicitly uses the header 'Directors’ Dealings' and contains detailed information about a transaction (Purchase) made by a person in a managerial position ('Dr. Hans-Georg Giering, Position: Member of an administrative or supervisory body'). This directly matches the definition for Director's Dealing reports, which corresponds to the filing code DIRS.
2014-06-17 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states it is a 'Dissemination of a Voting Rights Announcement'. It details that SBF Sächsische Beteiligungsfonds GmbH informed the company that its voting rights fell below the 3% threshold according to Article 21, Section 1 of the WpHG. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is short (1373 chars), but the content is the announcement itself, not just a notice that an announcement was published, making DVA the most specific fit over RPA or RNS.
2014-06-03 English
Datum:23.05.2014
Annual Report Classification · 95% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Vita 34 AG for the fiscal year 2013. It includes the auditor's report (Bestätigungsvermerk), the balance sheet (Bilanz), the profit and loss statement (Gewinn- und Verlustrechnung), and the notes (Anhang). This constitutes a comprehensive annual financial report. While it is not the full 10-K (which is a US-specific SEC filing), it functions as the equivalent annual report for a German entity. Given the provided categories, '10-K' is the standard classification for a full annual report. FY 2013
2014-05-23 German
Vita 34 AG: Close Brothers Seydler Starts Coverage of Vita 34 Stock
Regulatory Filings Classification · 100% confidence The document is a short news release dated May 13, 2014, announcing that analysts at Close Brothers Seydler Research AG have started coverage of Vita 34 stock and published an initial research report with a 'buy' recommendation. The text explicitly states that the complete research report is available for download on the company website in the 'Investor Relations' section. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement whose primary purpose is to state that a report has been published and is available elsewhere classifies as a Report Publication Announcement (RPA). It is not the full research report itself (which might be classified as IP or AR depending on content, but here it's just an announcement of the report's existence).
2014-05-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.